Lactobacillus Casei: Double Blind Placebo Effect for Gut Health

The genus Lactobacillus is a heterogeneous group of lactic acid bacteria (LAB) with important implications in biotechnology. It is a predominant microorganism in the world of gastrointestinal health, but various other uses are being explored. They have long been considered in the generally recognized as safe (GRAS) category by the Food and Drug Authority (FDA). They have been extensively used in fermentation and there is growing interest regarding their use in gut health, vaccine production, and biomedical innovation. This chapter highlights the application of lactobacilli in healthcare.

Source

A method for screening personalized probiotics, prebiotics, foods, health functional foods, and drugs using fecal samples and a proprietary medium composition. The method involves treating fecal samples with candidate materials, culturing, and analyzing the resulting microbiota and metabolites to identify effective personalized microbiota-improving agents. The composition includes L-cysteine, sodium chloride, sodium carbonate, potassium chloride, and hemin, which are combined with fecal samples to create a controlled in vitro environment that mimics the human gut. The method enables rapid screening of personalized microbiota-improving agents using fecal samples and special media, and can be used to diagnose diseases caused by intestinal disorders.

Source

Probiotics, particularly those native to the gut microbiota, have a profound influence on the gut environment. In this study, we conducted a randomized placebo-controlled, double-blind, parallel-group comparison trial to investigate the effects of Bifidobacterium longum BB536 (B. longum BB536) on the fecal microbiota and metabolite compositions in healthy individuals. We compared the effects of fermented milk produced solely with Streptococcus thermophiles and Lactobacillus bulgaricus (placebo group) and fermented milk supplemented with B. longum BB536 (BY group). Our findings revealed a significantly greater relative abundance of Faecalibacterium in the BY group than in the placebo group by the 3rd day, a trend that persisted until the end of the trial on the 17th day. Additionally, the BY group presented significantly increased concentrations of tryptophan (Trp), Indole-3-lactic acid, and Indole-3-aldehyde on the 17th day. A significant positive correlation was observed between the relative abundance of Faecalibacterium and the number of viable B. longum BB536 bacteria in the feces... Read More

Source

Probiotics, such as

Source

Abstract The gut microbiota harbors a complex ecosystem of bacteria that govern host health homeostasis. Alterations to the intestinal environment, known as gut dysbiosis, is associated with several diseases. Targeting the gut with microbiome-engineered therapeutics, such as probiotics, is a promising approach to restore microbial homeostasis and host health. Probiotics can effectively improve the gut environment, although strain-specific mechanisms remain largely unknown. Thus, this study aims to identify beneficial action of select probiotics to modulate the gut environment through antioxidative and anti-inflammatory properties. To this end, we tested the interaction among three probiotic strains Lactobacillus gasseri A237 (LgA237), Lactobacillus plan-tarum WCFS1 (LpWCFS1) and Lactobacillus fermentum NCIMB 5221 (Lf5221) and a human intestinal epithelial cell line, HT-29, for adhesion properties, radical scavenging abilities and anti-inflammatory activities. All three probiotics adhere well to HT-29 cells, indicating proper gut colonization. LpWCFS1 demonstrated the greatest adh... Read More

Source

Probiotics play diverse roles in promoting health and well-being, encompassing gut microbiota balance, digestive health, immune function, gut barrier integrity, metabolic health, and mental well-being. With the beneficial effects of probiotics, individuals may improve their gastrointestinal health, boost immune function, and reduce the risk of various diseases. These probiotics compete with pathogens and support gut and immune homeostasis to help in the prevention and cure of gastrointestinal disease, immune disorders, diabetes, obesity, cancer and allergic disorders, etc. Probiotic-rich foods and supplements into the diet offer a proactive approach to maintaining overall health and optimizing the functioning of the gut. Probiotics help to maintain immune homeostasis and decrease the risk of inflammatory disorders and allergic conditions. Several probiotic strains are available on the market and are being consumed in the form of foods, supplements, or drugs for health benefits. Lactobacilli, Bifidobacteria, and Bacillus species are common probiotic strains.

Source

Probiotics have shown potential in managing hypercholesterolemia and related metabolic conditions. This study evaluated the effects of Lactocaseibacillus (Lactobacillus) paracasei sup. paracasei TISTR 2593 on the gut microbiome and metabolic health in patients with hypercholesterolemia, and was registered in the Thai Clinical Trial Registry (TCTR 20220917002). In a randomized, double-blind, placebo-controlled trial, 22 hypercholesterolemic participants received either the probiotic or a placebo daily for 90 days. Fecal samples collected before and after the intervention revealed significant microbiome changes, including a decrease in Subdoligranulum, linked to rheumatoid arthritis, and an increase in Flavonifractor, known for its anti-inflammatory properties. Additionally, the probiotic group exhibited a significant reduction in low-density lipoprotein cholesterol (LDL-C) levels. These findings suggest that L. paracasei TISTR 2593 can modulate the gut microbiome and improve metabolic health, warranting further investigation into its mechanisms and long-term benefits.

Source

The gut microbiota is the central regulator of human metabolism, it is considered a superorganism, it fulfills functions related to homeostasis and the maintenance of systemic health, contributing to immunity and epithelial integrity, any alteration is related to non-compliance or interruption of some of its functions, for this reason in search of balance, prevention and treatment measures have been implemented, one of them is the use of probiotics, which has been proven to bring beneficial actions towards the health of the host. , such as lactobacillus and bifidobacteria, here we will review the association between gut microbiota, probiotics and the use of probiotics like a treatment of prevention for pathologies of gut microbiota.

Source

Abstract Background and Aims Probiotics may play a role in inflammation, nutritional status, kidney function and quality of life. However, few studies were performed to study the effects of probiotics on metabolites of intestinal flora in patients. Method We investigated the effects of Lactobacillus paracasei N1115 on intestinal flora and related short-chain fatty acids in end stage kidney disease patients on peritoneal dialysis (PD) in a single-center, prospective, randomized, double-blind, placebo-controlled study (ChiCTR-TRC2016254). Fifty one patients on peritoneal dialysis underwent an intervention with the probiotic supplement (n = 36, PR group) or placebo (n = 15, PL group) for twelve weeks. In addition to collecting fecal samples for 16S rRNA gene high-throughput sequencing and short-chain fatty acids (SCFAs) analysis, gastrointestinal symptom was also assessed at baseline and after the intervention. Moreover, PR group was divided into gastrointestinal symptom remission group (n = 30, GR group) and gastrointestinal symptom non-remission group (n = 5, GNR group). Results Probi... Read More

Source

As our understanding of the intricate interaction between gut bacteria and human health continues to expand, so too has interest in the ability of probiotics to manage gut microbiota and confer multiple health benefits to the host. The mini literature review focuses on the expanding potential of the use of probiotics in GI health, with a focus on probiotics' potential therapeutic advantages in a variety of gastrointestinal (GI) illnesses. Probiotics play a significant role in managing diarrhea and symptoms of irritable bowel syndrome with diarrhea (IBS-D) by modulating gut microbial communities. Specific probiotic strains have been found to reduce the abundance of harmful bacteria, regulate inflammatory markers like interleukin 6, and improve GI symptoms such as abdominal discomfort and stool consistency. Additionally, probiotic blends have shown potential for preventing GI infections and alleviating GI pain in IBS-D patients. Studies have demonstrated that certain multi-strain probiotics, including Bifidobacterium and Lactobacillus species, can significantly increase the frequency o... Read More

Source

The probiotics, when administered in adequate amounts, have the ability to 
 confer health benefits to the host by positively influencing the composition and 
 function of gut microbiota. The present study was aimed to isolate and 
 characterize the probiotic bacteria from locally available curd and Yakult 
 samples and compare them with Sporolac for probiotic properties. Three 
 bacterial isolates were isolated and tentatively identified on morpho-cultural and 
 biochemical characteristics as Lactobacillus sp. The isolates were named 
 Lactobacillus sp. isolates PBC, PBY and SPO. E coli was used as negative control. 
 The study revealed that the isolates exhibited auto-aggregation and co 
 aggregation activities, more in isolate SPO as compared to the isolates PBC and 
 PBY. Biofilm and quorum quenching activities were high in Lactobacillus sp. 
 isolate PBC and PBY as compared to Lactobacillus sp. isolate SPO. The other 
 tests showed more or less similar properties as compared to the commercially 
 available product.... Read More

Source

The human gut microbiome, crucial for health, can be disrupted by antibiotic treatment, leading to various health issues and the rise of antimicrobial resistance (AMR). This study investigates the impact of a probiotic on the gut microbiomes composition and antimicrobial resistance genes (ARGs) content following antibiotic treatment. Conducted as a single-centre, double-blind, randomized, placebo-controlled trial, adults taking oral antibiotics were allocated into a probiotic or placebo group. Evaluations included viable cell enumeration and shotgun metagenomic sequencing for microbiome analysis, along with ARG assessment. The probiotic maintained the numbers of lactobacilli, significantly increased the Bacteroides population and decreased numbers of enterobacteria. The lactobacilli and enterococci numbers decreased in the placebo. The alpha diversity remained stable in the probiotic group throughout the study, but significant reductions were observed in the placebo group post antibiotic treatment. There was significant spatial separation in beta diversities between groups at the en... Read More

Source

Agents for stimulating the growth of bifidobacteria in the mammalian gut, comprising Lactobacillus fermentum cells, Lactobacillus delbrueckii cells, or a combination of both, as well as their culture medium, which can be administered in various forms including LACTEOL, low-lactose LACTEOL, or supernatant fractions. These agents can be used to improve gut health by increasing bifidobacteria populations, which has been linked to various beneficial effects including reduced inflammation, improved metabolic function, and enhanced immune response.

Source

Personalized probiotic regimens, taking into account individual characteristics such as stool patterns, have the potential to alleviate gastrointestinal disorders and improve gut health while avoiding the variability exhibited among individuals by conventional probiotics. This study aimed to explore the efficacy of personalized probiotic interventions in managing distinct stool patterns (constipation and diarrhea) by investigating their impact on the gut microbiome and gastrointestinal symptoms using a prospective, randomized, double-blind, placebo-controlled clinical trial design. This research leverages the multi-strain probiotic formulas, Consti-Biome and Sensi-Biome, which have previously demonstrated efficacy in alleviating constipation and diarrhea symptoms, respectively. Improvement in clinical symptoms improvement and compositional changes in the gut microbiome were analyzed in participants with predominant constipation or diarrhea symptoms. Results indicate that tailored probiotics could improve constipation and diarrhea by promoting

Source

Abstract: This study explores the potential of using probiotic lactic acid bacteria (LAB) that produce bacteriocins as a novel approach to controlling gut microbiota dysbiosis. Gut dysbiosis, characterized by an imbalance in the composition of the gut microbiota, is implicated in various health disorders. Probiotic LAB have gained attention for their ability to promote a balanced gut microbiota. Bacteriocin-producing LAB offer an added advantage by inhibiting pathogenic bacteria and promoting the growth of beneficial microbes. This review summarizes the current knowledge on the mechanisms of probiotic LAB and their bacteriocins in modulating gut microbiota composition. Additionally, key clinical studies and potential applications of bacteriocin-producing LAB in mitigating gut dysbiosis are discussed.

Source

Background: Several studies hypothesized a therapeutic role of probiotics in the management of chronic bacterial prostatitis (CBP) patients. Here, we assessed the effect of probiotics as an add-on treatment in patients with clinical recurrences of CBP, through gut microbiota modification analysis. Methods: This study has been planned as a randomized, double-blind, placebo-controlled, multicenter clinical trial examining the efficacy and safety of consumption of probiotics containing human Lactobacillus casei DG or placebo following 1 month-treatment with ciprofloxacin. Twenty-four patients with CBP were recruited and treated for 3 months with placebo (n. 12) or with Lactobacillus Casei DG (n. 12). During the enrollment and follow-ups, IPSS, NIH-CPSI and SF-36 were used. Urological examinations and microbiological tests were performed to analyze the symptomatology, recurrences frequency, and gut and seminal microbiota. Results: The treatment with Lactobacillus Casei DG induced a significantly (p<0.01) faster recovery of symptoms (2 days vs. 8 days) than placebo and an in... Read More

Source

This was a sub-group analysis of a multicentre, randomised, placebo-controlled, double-blind trial (ECLISP trial) OBJECTIVES: To assess the efficacy of a probiotic containing at least 6.5 10

Source

Abstract BACKGROUND Lactocaseibacillus paracasei subsp. paracasei NTU 101 (NTU101) is a wellknown commercial probiotic with multiple health beneficial effects. In this study, the gut microbiota modulation effect of an NTU 101 product, Vigiis 101LAB, on healthy human was investigated in a randomized, doubleblind, placebocontrolled human trial. RESULTS Vigiis 101LAB significantly modulated human gut microbiota at fourth and sixth weeks of trial (anosim analysis, P = 0.001). It also significantly improved peristalsis ( P = 0.003) and shortened defecation interval of subjects. The shift of gut microbiota is significantly fit with defecation interval ( P = 0.009) and stool shape ( P = 0.001) of subjects. CONCLUSION Our results suggest that Vigiis 101LAB promotes human intestinal health with improvement of peristalsis and fecal quality. The gut modulation effects of Vigiis 101LAB subsequently raised the abundance of vitamin B7, vitamin K, pyrimidine and purine biosynthesis pathways. Vigiis 101LAB may promote peristalsis via purinergic pathway and possibly conferring prophylactic be... Read More

Source

<title>Abstract</title> <bold>Background &amp; Aims:</bold> Constipation is a disorder affecting the quality of life of patients, and symptoms following current treatments still need to be improved. Although probiotics treat constipation, the efficacy and safety of this therapy remain controversial. This a randomized, double-blind, placebo-dense controlled trialaimed to investigate the clinical impact of the probiotic bacterium Lacticaseibacillus<italic> paracasei</italic> 207-27 on chronic constipation. <bold>Methods</bold>: We recruited 80 patients aged 1865 with chronic constipation and divided them into probiotic (<italic>Lacticaseibacillus paracasei</italic> 207-27) and placebo (maltodextrin) groups. The participants were treated twice daily for 4 weeks, and stool samples and questionnaires were collected before and after treatment. The 16S rRNA sequencing and untargeted metabolomics data were analyzed. <bold>Results</bold>: Bowel movements, total short-chain fatty acid, and propionic acid were significantly improved in the probiotic group compared with in the placebo (control)... Read More

Source

In recent years, interest in probiotics, particularly Lactobacillus strains like Lactobacillus sp. SKG34, isolated from Sumbawa mare milk, has surged due to their potential health benefits. This strain holds promise as a probiotic agent, but understanding its behavior in the gastrointestinal (GI) tract is essential for effective application. This study aimed to investigate the resistance and persistence of Lactobacillus sp. SKG34 in the GI tract of rats. Rats were orally administered the strain at a concentration of 10^8 cells for 30 days. The probiotics ability to modulate gut microbiota and improve host health is a key area of interest. By utilizing techniques like PCR-RAPD, this research sought to elucidate the fate of Lactobacillus sp. SKG34 in the complex environment of the rat GI tract. Results revealed a significant increase in LAB population in cecal contents, from 3.06 x 10^9 cfu/g in the control group to 1.25 x 10^10 cfu/g in the probiotic group. RAPD analysis also detected Lactobacillus sp. SKG34 in approximately 23% of the total population of lactic acid bacteria in ceca... Read More

Source